Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. Recently, a subset of these same mutations of ACVR1 have b...
Príomhchruthaitheoirí: | Mohedas, A, Wang, Y, Sanvitale, C, Canning, P, Choi, S, Xing, X, Bullock, A, Cuny, G, Yu, P |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2014
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
de réir: Chaikuad, A, et al.
Foilsithe / Cruthaithe: (2012) -
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva
de réir: Chaikuad, A, et al.
Foilsithe / Cruthaithe: (2012) -
Investigation of kinase activation in fibrodysplasia ossificans progressiva
de réir: Sanvitale, CE
Foilsithe / Cruthaithe: (2014) -
FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
de réir: Mehul M Gosai, et al.
Foilsithe / Cruthaithe: (2013-03-01) -
Fibrodysplasia ossificans progressiva
de réir: Chané Smit, et al.
Foilsithe / Cruthaithe: (2023-11-01)